TORONTO, Dec. 9, 2021 /CNW/ - Tripsitter Clinic Ltd. (the "Company") provided the following update with respect to the board of directors: Alexander Somjen has been appointed to the board of Directors, effective as of December 8, 2021.
Mr. Somjen has extensive experience serving as an officer and director of publicly listed and privately held companies across a broad range of sectors including technology, healthcare and cannabis. Most recently, Alexander served as President of a publicly traded, California based multi-state cannabis company and CEO of a publicly traded global investment company. Alexander currently serves as CEO of an investment company focused on early-stage investment opportunities in the Psychedelics Sector. Prior to that, Alexander spent over a decade in capital markets at a large financial institution working in both investment banking and sales and trading related capacities. Alexander holds an MBA from IE Business School.
On behalf of the board, "We are pleased to welcome Alexander to the board. I'm confident that Alexander's knowledge and experience will be a valuable addition to our Board of Directors," said Dr. John Huber, Chief Executive Officer.
For further information concerning the Company and its business, please see the long form prospectus dated November 22, 2021 (the "Prospectus") supporting its application for listing on the CSE. A copy of the Prospectus was filed under the Company's profile at www.sedar.com.
About TripSitter Clinic Ltd.
TripSitter, through its wholly-owned subsidiary, TripSitter Clinic Corp., operates a consultative virtual clinic and tele-health platform that connects prospective patients to a licensed physician in the United States who can evaluate for a prescribed treatment program of low-dose, oral ketamine medication. The licensed physicians within the platform consult and coordinate with the primary care physician ("PCP") of the prospective patient, if they are approved for treatment. TripSitter is not a PCP and requires each prospective patient to provide their information to their PCP during the initial intake process. The PCP is assigned to the patient by the patient's own physician. TripSitter is proud to be at the forefront of the emerging wave of consultative medicine that prioritizes patient access and quality of care while leveraging an internationally recognized platform of remote diagnostic and patient monitoring. TripSitter's platform, TripSitter.Clinic, is a mobile-first, responsive webapp that acts as a virtual clinic, connecting patients with licensed medical practitioners. TripSitter.Clinic operates as a SaaS platform, functioning as the intermediary between patient and practitioner.
ON BEHALF OF THE BOARD of DIRECTORS
"Dr. John Huber"
Dr. John Huber
CEO
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of TripSitter in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the securities may not be offered or sold within the U.S. or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.
Disclaimer for Forward-Looking Information
This news release includes certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Forward-looking information in this news release includes statements concerning the Company's general business plans, the tele-health industry and the Company's market position within it, and statements concerning the listing of the Company's common shares on the CSE. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Company's final long-form prospectus dated November 22, 2021, and the schedules attached thereto, that are available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.
SOURCE TripSitter Clinic Ltd.
Corporate: Dr. John Huber, CEO, TripSitter Clinic Ltd., [email protected], 512-577-5044; Investors/Media: [email protected]
Share this article